Biochemical and pharmacological activity of novel 8- fluoroanthracyclines: Influence of stereochemistry and conformation

Molecular Pharmacology

Volumn 50, Issue 3, 1996, Pages 603-609

  Animati, Fabio ^b   Arcamone, Federico ^b   Bigioni, Mario ^b   Capranico, Giovanni ^a   Caserini, Claudia ^a   De Cesare, Michelandrea ^a   Lombardi, Paolo ^b   Pratesi, Graziella ^a   Salvatore, Carmela ^b   Supino, Rosanna ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 FLUOROIDARUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IDARUBICIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA CLEAVAGE; DRUG CONFORMATION; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; PRIORITY JOURNAL; STEREOCHEMISTRY; TUMOR XENOGRAFT;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL SURVIVAL; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; FEMALE; FLUORINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 9544232513     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19:670-686 (1992).
2. Zunino, F., and G. Capranico. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Design 5:307-317 (1990).
3. Capranico, G., R. Supino, M. Binaschi, L. Capolongo, M. Grandi, A. Suarato, and F. Zunino. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. 45:908-915 (1994).
4. Capranico, G., and F. Zunino. Antitumor inhibitors of DNA topoisomerases. Curr. Pharm. Design 1:1-14 (1995).
5. Capranico, G., C. Soranzo, and F. Zunino. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res. 46:5499-5503 (1986).
6. Wang, A. H., G. Ughetto, G. J. Higley, and A. Rich. Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complex to d(CpGpTpApCpG) at 1.2 A resolution. Biochemistry 26:1152-1163 (1987).
7. Lombardi, P., F. Animati, A. Cipollone, G. Giannini, E. Monteagudo, and F. Arcamone. Synthesis and conformational preference of novel 8-fluoro-anthracyclines. Acta Biochim. Pol. 42:433-444 (1995).
8. Del Nero, S., and P. Lombardi. A Diels-Alder synthetic approach to racemic 4-demethoxydaunomycinone. Gazz. Chim. Ital. 114:517-520 (1984).
9. Haasnoot, C. A. G., F. A. A. M. de Leeuw, and C. Altona. The relation between proton-proton NMR coupling constants and substituent electronegativities. I. An empirical generalization of the Karplus equation. Tetrahedron 36:2783-2792 (1980).
10. Castellano, S., and A. A. Bothner-By. Analysis of NMR spectra by least squares. J. Chem. Phys. 41:3863-3869 (1964).
11. Binaschi, M., R. Supino, R. A. Gambetta, G. Giaccone, E. Prosperi, G. Capranico, I. Cataldo, and F. Zunino. MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int. J. Cancer 62:84-89 (1995).
12. Geran, R. I., R. H. Greenberg, M. M. Macdonald, A. M. Schumacher, and B. J. Abbott. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3:1-88 (1972).
13. Arcamone, F. Doxorubicin, in Medicinal Chemistry Series (G. Stevens, ed.). Academic Press, New York (1981).
14. Penco, S., A. Vigevani, Tosi C., R. Fusco, D. Borghi, and F. Arcamone. Conformational flexibility of ring A in a series of substituted anthracyclines: 1H-n.m.r. and quantum mechanical studies. Anticancer Drug Design 1:161-165 (1986).
15. Arcamone, F., G. Cassinelli, G. Franceschi, R. Mondelli, P. Orezzi, and S. Penco. Struttura e stereochimica della daunomicina. Gazz. Chim. Ital. 100:949-989 (1970).
16. Ragg, E., C. Ulbright, R. Mondelli, G. Fronza, and S. Penco. Conformational analysis of doxorubicin and analogues in aqueous inversion recovery difference NOE spectroscopy. Gazz. Chim. Ital. 120:501-509 (1990).
17. Zunino, F., and G. Capranico. Sequence-selective groove binders, in The Cancer Therapeutics Handbook (B. Teicher, ed.). Humana Press, Totowa, NJ, in press (1996).
18. Moore, M. H., W. N. Hunter, B. L. d'Estaintot, and O. Kennard. DNA-drug interactions: the crystal structure of d(CGATCG) complexed with daunomycin. J. Mol. Biol. 206:693-705 (1989).
19. Ishikawa, T., K. Akimaru, M. T. Kuo, W. Priebe, and M. Suzuki. How does the MRP/GS-X pump export doxorubicin? J. Natl. Cancer Inst. 87:1639-1640 (1995).